Regulation of Multi-drug Resistance in hepatocellular carcinoma cells is TRPC6/Calcium Dependent

Wen, Liang; Liang, Chao; Chen, Enjiang; Chen, Wei; Liang, Feng; Zhi, Xiao; Wei, Tao; Xue, Fei; Li, Guogang; Yang, Qi; Gong, Weihua; Feng, Xinhua; Bai, Xueli; Liang, Tingbo

doi:10.1038/srep23269

Download PDF

Article
Open access
Published: 24 March 2016

Regulation of Multi-drug Resistance in hepatocellular carcinoma cells is TRPC6/Calcium Dependent

Liang Wen¹^na1,
Chao Liang²^na1,
Enjiang Chen¹,
Wei Chen¹,
Feng Liang³,
Xiao Zhi¹,
Tao Wei¹,
Fei Xue⁴,
Guogang Li¹,
Qi Yang⁵,
Weihua Gong¹,
Xinhua Feng⁶,
Xueli Bai¹ &
…
Tingbo Liang^1,7

Scientific Reports volume 6, Article number: 23269 (2016) Cite this article

6038 Accesses
85 Citations
6 Altmetric
Metrics details

Subjects

Abstract

Hepatocellular carcinoma (HCC) is notoriously refractory to chemotherapy because of its tendency to develop multi-drug resistance (MDR), whose various underlying mechanisms make it difficult to target. The calcium signalling pathway is associated with many cellular biological activities, and is also a critical player in cancer. However, its role in modulating tumour MDR remains unclear. In this study, stimulation by doxorubicin, hypoxia and ionizing radiation was used to induce MDR in HCC cells. A sustained aggregation of intracellular calcium was observed upon these stimuli, while inhibition of calcium signalling enhanced the cells’ sensitivity to various drugs by attenuating epithelial-mesenchymal transition (EMT), Hif1-α signalling and DNA damage repair. The effect of calcium signalling is mediated via transient receptor potential canonical 6 (TRPC6), a subtype of calcium-permeable channel. An in vivo xenograft model of HCC further confirmed that inhibiting TRPC6 enhanced the efficacy of doxorubicin. In addition, we deduced that STAT3 activation is a downstream signalling pathway in MDR. Collectively, this study demonstrated that the various mechanisms regulating MDR in HCC cells are calcium dependent through the TRPC6/calcium/STAT3 pathway. We propose that targeting TRPC6 in HCC may be a novel antineoplastic strategy, especially combined with chemotherapy.

KRAS mutation: from undruggable to druggable in cancer

Article Open access 15 November 2021

Lamei Huang, Zhixing Guo, … Liwu Fu

The selective prolyl hydroxylase inhibitor IOX5 stabilizes HIF-1α and compromises development and progression of acute myeloid leukemia

Article Open access 18 April 2024

Hannah Lawson, James P. Holt-Martyn, … Kamil R. Kranc

Ferroptosis: mechanisms, biology and role in disease

Article 25 January 2021

Xuejun Jiang, Brent R. Stockwell & Marcus Conrad

Introduction

Recently, the development of antineoplastic drugs has made great progress. However, their limited curative efficacy still remains a clinical obstacle, which is mainly ascribed to multi-drug resistance (MDR), induced by conventional drugs and also by new “targeted” drugs^1,2. MDR also occurs in other situations, such as the hypoxic condition inside solid tumours^3,4, making exploring the mechanisms of MDR a research hotspot. Numerous studies have revealed that MDR is associated with overexpression of certain drug efflux pumps⁵, epithelial mesenchymal transition (EMT)^6,7, the hypoxia-inducible factor1-α (Hif1-α) signalling pathway⁸, DNA damage repair^1,9,10,11, autophagy induction¹² and epigenetic regulation¹³. Recently, some new factors such as cancer stem cell¹⁴, miRNAs¹⁵ and immunosuppressive microenvironment¹⁶, have also been implicated in MDR, rendering the mechanisms of MDR rather complicated.

Hepatocellular carcinoma (HCC) is an extremely malignant tumour with low sensitivity to chemotherapy, in part caused by MDR¹⁷. Several mechanisms govern MDR induction, among which drug efflux pump, EMT, Hif1-α signalling and DNA damage repair play vital roles in the chemo-resistance of HCC^16,18,19,20. It is frequently observed that one mechanism cannot be fully responsible for acquired chemo-resistance to drugs; therefore, a strategy targeting one mechanism alone is always poorly effective. Studies on the relationships between various MDR mechanisms are scarce. Therefore, identifying a common key signalling pathway is a promising approach to improve the efficacy of chemotherapy. Herein, HCC cells were treated by stimulation with doxorubicin, hypoxia and ionizing radiation, representing three models of MDR, to identify for possible common signalling events related to crucial MDR mechanisms.

Intracellular calcium is a versatile second messenger that is involved in many physical and pathological processes. The calcium signalling pathway plays a vital role in tumour cells, via apoptosis, proliferation, invasion and metastasis²¹. Some studies demonstrated that MDR-relevant mechanisms of EMT, hypoxia-induced Hif1-α signalling pathway and DNA damage repair are closely related to intracellular calcium. In breast cancer cells, various stimuli-induced EMT are dependent on changes in non-stimulated store-operated calcium entry^22,23, partly via calcium channel TRPM7²⁴. In addition, calcium participates in enhanced Hif-1 transcriptional activity in cells under hypoxia^25,26. Calcium is also an important co-factor in genotoxic stress from poly polymerase-1 hyperactivation after reactive oxygen species (ROS)-induced DNA damage-related alterations in cellular metabolism and DNA repair²⁷. However, there have been few studies on the common interactions between intracellular calcium and enhanced drug resistance driven by these mechanisms.

Intracellular calcium homeostasis is regulated by the calcium channels/pumps, mostly in the cell membrane and endoplasmic reticulum. In oncology, altered expressions of specific calcium channels and pumps are characteristic features of certain cancers²⁸ and have been studied thoroughly in recent years. Interestingly, among all the calcium channels/pumps, transient receptor potential (TRP) calcium channels have come to our attention because of their wide roles in malignant behaviours of cancer cells, including proliferation, migration and invasiveness^28,29. Indeed, it was reported that TRP canonical 5 (TRPC5) is essential for P-glycoprotein (P-gp) induction in drug-resistant cancer cells³⁰. Even so, there are few studies connecting the role of TRP channels with chemotherapy resistance. Specifically in liver cancer, both TRP canonical 6 (TRPC6) and TRP canonical 1 (TRPC1) are associated with cell proliferation³¹. TRPC6 is poorly expressed in normal hepatocytes, but highly expressed in liver carcinoma samples³². However, the role of TRP calcium channels in chemo-resistance through calcium is seldom studied and still remains unclear. Hence, in this study, we explored the roles of intracellular calcium on various MDR relevant mechanisms, and further investigated its upstream TRP calcium channel and the common downstream regulator in HCC cells.

Results

Stimulation by doxorubicin, hypoxia or ionizing radiation enhance HCC cells’ resistance to multiple drugs

To study MDR relevant mechanisms in HCC, cells were separately treated with doxorubicin, hypoxia and ionizing radiation to build three acquired MDR models. The optimal dose and duration of the various stimuli were determined according to previous reports and our preliminary experiments (see Supplementary Fig. S1) to ensure stable MDR induction. After various stimuli, the altered cells’ resistance to multiple drugs was assessed by drug sensitivity assays using three widely used drugs. Doxorubicin, hypoxia and ionizing radiation all significantly decreased the cells’ sensitivity to doxorubicin, 5-fluorouracil and cisplatin (Fig. 1). The mean IC₅₀ (half maximal inhibitory concentration) values of multiple drugs in HCC cells, determined by full-range concentrations of the various drugs, were significantly elevated compared with groups not exposed to stimuli (Table 1), which was consistent with the results shown in Fig. 1. Thus, stimulation using doxorubicin, hypoxia or ionizing radiation successfully induced MDR in HCC cells.

**Figure 1: Enhanced multi-drug resistance induced by various stimuli.**

Table 1 IC₅₀ values of multiple drugs in HCC cells treated with doxorubicin (0.2 μg/mL) (Pre-Dox), hypoxia (1% O₂), ionizing radiation (10 Gy) (Pre-IR), compared with control groups (normality) (n = 6).

Full size table

Sustained aggregation of intracellular calcium participates during various stimuli

We next explored the effects of these three stimuli on intracellular cytosolic free calcium ([Ca²⁺]_c) in HCC cells. Deferoxamine (DFO), an Fe chelating agent that was reported as an Hif1-α and Hif1-α-dependent proteins inducer^33,34, was applied as a hypoxia analogue. The ability of certain stimuli (e.g., mechanical scratch, growth factors) to increase [Ca²⁺]_c is always transient and sometimes shows a spatial and temporal aspect³⁵. However, doxorubicin or DFO failed to induce a rapid [Ca²⁺]_c aggregation or evident fluctuation, compared with the control group (Fig. 2a and see Supplementary Video 1, 2, 3 and 4). Quantitative analysis of [Ca²⁺]_c aggregation (Fig. 2b) and the maximal contents of [Ca²⁺]_c (Fig. 2c) during these stimuli in Huh7 cells showed the same result. The same phenomenon was also observed in HepG2 cells (see Supplementary Fig. S2 and Video 5, 6, 7 and 8).

**Figure 2: Various stimuli produce a significantly long-term and sustained, but not immediate, increase in cytosolic calcium.**

We then tested long-term [Ca²⁺]_c changes in HCC cells. The [Ca²⁺]_c fluorescence intensity was measured (Fig. 2d) after various stimuli within 24 h. Separated by the vertical split line, cells with relatively more [Ca²⁺]_c were defined as [Ca²⁺]_c positive cells. The percentage of [Ca²⁺]_c positive cells among those treated by doxorubicin gradually increased at 12 h (51.3%) and 24 h (56.9%), compared with the untreated group (37.9%). In HepG2 cells, the percentage was 47.0% (control), 58.1% (12 h) and 73.3% (24 h). Under hypoxia, the percentage of [Ca²⁺]_c positive cells also increased at 6 h (60.1% (Huh7) and 62.2% (HepG2)) and 24 h (85.5% (Huh7) and 87.0% (HepG2)), compared with the untreated groups (50.9% (Huh7) and 52.0% (HepG2)). Similarly, the percentage of [Ca²⁺]_c positive cells increased both 2 h (76.8% (Huh7) and 79.4% (HepG2)) and 24 h (67.0% (Huh7) and 73.3% (HepG2)) after exposure to ionizing radiation, compared with the untreated groups (51.3% (Huh7) and 50.3% (HepG2)). Repeated experiments gave the same results. The relative percentages of [Ca²⁺]_c positive cells were calculated and analysed (see Supplementary Fig. S3). These results demonstrated that under long-term stimulation by doxorubicin, hypoxia or a long time after ionizing radiation, HCC cells could maintain a sustained aggregation of intracellular calcium, indicating that long-term elevation of [Ca²⁺]_c is more likely to play a significant role in cells’ response to various stimuli.

Intracellular calcium chelation inhibits stimuli-induced MDR and its relevant mechanisms

Based on various observed simultaneous stimuli-induced MDR and [Ca²⁺]_c elevation, we investigated whether calcium signalling participates in MDR. Before applying various stimuli, HCC cells were pretreated with the intracellular calcium chelator, BAPTA-AM, at a maximal dose (10 μM), which has been shown to be not significantly toxic to normal HCC cells over the duration of the stimuli (see Supplementary Fig. S4). And calcium chelation affected the drug sensitivity of unstimulated cells to drugs very slightly (Fig. 3a and see Supplementary Fig. S5). However, after stimulation with doxorubicin, hypoxia or ionizing radiation, we found intracellular calcium chelation significantly attenuated the cells’ resistance to various drugs (Fig. 3(b–d) and see Supplementary Fig. S5). And the mean IC₅₀ values of drugs were presented to further assess the altered drug sensitivity of HCC cells with calcium chelation (see Supplementary Table S1). Taken together these data indicated that intracellular calcium is involved in the MDR induced by various stimuli in HCC cells.

Upregulation of ABC transporters and induction of EMT are mainly responsible for doxorubicin-induced MDR, which were well studied in HCC in our previous published studies^36,37. Preliminary experiments revealed that calcium chelation failed to inhibit doxorubicin-induced upregulations of ABC transporters (see Supplementary Fig. S6) but not EMT (supported by the following data); therefore, EMT was selected in this study. Hif1-α signalling under hypoxia and DNA damage repair in radiation treatment are widely regarded as the crucial responding mechanisms¹⁵. Specifically, Twist and H2A.X play crucial roles in doxorubicin-induced EMT⁶ and ionizing radiation-induced DNA damage repair³⁸, respectively. Indeed, we confirmed that the mechanisms of EMT, Hif1-α signalling and DNA damage repair play roles in regulating MDR induced by doxorubicin, hypoxia and ionizing radiation, using short interfering RNA (siRNA) downregulation of Twist, Hif1-α and H2A.X (see Supplementary Fig. S7), respectively. That was the rationale for selecting EMT, Hif1-α signalling and DNA damage repair as the model mechanisms to investigate MDR corresponding to various stimuli in this study.

The role of intracellular calcium in regulating these three mechanisms was then examined. We found that doxorubicin reduced the expression of E-Cadherin and Claudin1 and upregulated Vimentin, while calcium chelation reversed the doxorubicin-induced expression changes of EMT markers (Fig. 4a). In addition, calcium chelation also reversed the spindle-like morphology of HCC cells induced by doxorubicin to a grape-like one (see Supplementary Fig. S8a). For the hypoxia-induced Hif1-α signalling pathway, calcium chelation blocked the expression of hypoxia-induced Hif1-α strongly (Fig. 4b). As for the third mechanism, to assess DNA damage repair activation induced by ionizing radiation, the phosphorylation of H2A.X, ATM and ATR, were chosen as classical proteins. At 2 h after ionizing radiation treatment, calcium chelation decreased the phosphorylation of ATM, ATR and H2A.X in HCC cells. By contrast, 24 h after ionizing radiation, groups with calcium chelation showed a relatively higher expression of p-ATM, p-ATR and p-H2A.X, compared with the groups treated with ionizing radiation alone (Fig. 4c). We then compared the relative expression levels of p-H2A.X at the 2 h and 24 h time points simultaneously to assess the overall influence of calcium chelation. And the result showed that p-H2A.X expression at 24 h after ionizing radiation, regardless of calcium chelation, was much lower than that at 2 h (Fig. 4d), indicating that the peak of DNA damage repair activation appears at an early stage and DNA damage repair was more affected by calcium chelation at the 2 h time point. In addition, a comet assay revealed that calcium chelation significantly increased the severity of DNA damage after ionizing radiation (see Supplementary Fig. S8(b,c)). Thus, on the whole, calcium chelation efficiently inhibited the cells’ capacity for DNA damage repair within 24 h after ionizing radiation. Taking into account that the marked expression of p-H2A.X 2 h after ionizing radiation was more responsible for DNA damage repair, the expressions of DNA damage repair proteins at 2 h time point after ionizing radiation were tested in the subsequent MDR relevant studies.

**Figure 4: Calcium chelation inhibits EMT, Hif1-α signalling and DNA damage repair, induced by doxorubicin, hypoxia and ionizing radiation respectively, in Huh7 and HepG2 cells.**

In summary, these findings demonstrated that in HCC cells, the MDR-related mechanisms, EMT, Hif1-α signalling and DNA damage repair, are all calcium dependent.

TRPC6 modulates calcium-dependent MDR

We next explored the potential calcium channel/pump responsible for intracellular calcium aggregation to regulate of MDR. Accumulating evidence has shown that the TRP channels are intimately associated with tumour behaviours. Huh7 and HepG2 cells mainly express TRPC1 and TRPC6³², which were considered first in our study. We found that in HCC cells, stimulation by doxorubicin, hypoxia and ionizing radiation significantly increased the mRNA expression of TRPC6 (Fig. 5a) but not of TRPC1 (data not shown). In addition, in HCC tissues, we found that TRPC6 expression is much higher in tumour tissues than in pericancerous tissues and is markedly related to a higher TNM classification (data not shown), suggesting that TRPC6 is closely associated with HCC’s malignant behaviours. Based on this, we hypothesized TRPC6 might also be responsible for HCC’s acquired MDR via calcium signalling.

**Figure 5: The TRPC6 channel plays a vital role in various mechanisms to regulate MDR via calcium in Huh7 and HepG2 cells.**

To explore the function of TRPC6 in regulating long-term [Ca²⁺]_c aggregation, the specific TRPC6 inhibitor, SKF-96365, was used. The results showed that SKF-96365 significantly reduced the number of [Ca²⁺]_c positive cells under any stimulus in HCC cells (Fig. 5b). This was confirmed by quantitative analysis (see Supplementary Fig. S9). Subsequently, both the TRPC6 inhibitor and a TRPC6 interfering siRNA (siTRPC6) were used to further clarify the role of TRPC6 in MDR. The efficiency of TRPC6 interference is shown in Supplementary Fig. S10. After TRPC6 interference, HCC cells showed significant attenuation of drug resistance under all three stimuli, as seen in Fig. 5(c–e) and Supplementary Fig. S11. TRPC6 inhibition could reverse doxorubicin-induced EMT (Fig. 5c), block hypoxia-induced Hif1-α expression (Fig. 5d) and inhibit DNA damage repair at 2 h after ionizing radiation (Fig. 5e).

These results demonstrated that the calcium channel TRPC6 plays a vital role in the sustained aggregation of [Ca²⁺]_c under various stimuli, which in turn is directly involved in regulating EMT, Hif1-α signalling and DNA damage repair.

STAT3 activation mediates calcium dependent MDR

The common bridge between calcium signalling and the downstream mechanisms remains unclear. Interestingly, the mechanisms of EMT, Hif1-α signalling and DNA damage repair were all reported to be regulated by phosphorylation of upstream proteins, such as Erk, AKT and STAT3^{39,40,41,42,43}, which were reported to promote drug resistance in tumours. Based on this, calcium dependent calmodulin phosphorylase targeted Erk1/2, AKT and STAT3 were hypothesized to connect calcium and MDR-relevant mechanisms^21,24. 2 h after various stimuli in HCC cells, calcium chelation markedly increased the expression of p-Erk1/2 and p-AKT. In contrast, calcium chelation decreased p-STAT3 expression (Fig. 6a and see Supplementary Fig. S12), which was consistent with the attenuated drug resistance. Furthermore, both calcium chelation and TRPC6 interference significantly inhibited the increased p-STAT3 expression by all stimuli at 24 h, 6 h and 2 h for doxorubicin, hypoxia and ionizing radiation (Fig. 6a and see Supplementary Fig. S13), respectively, indicating that STAT3 activation acts as a downstream regulator in TRPC6/calcium signalling.

**Figure 6: Phosphorylation of STAT3 (Tyr705) is blocked by intracellular calcium chelation and STAT3 inhibitor NSC74859 (100 μM) attenuates various MDR-related mechanisms in HCC cells.**

Furthermore, STAT3 inhibition by NSC74859^44,45 also significantly attenuated various stimuli-induced resistance to doxorubicin (see Supplementary Fig. S14). In terms of the mechanism, NSC74859 reversed doxorubicin-induced EMT, blocked hypoxia-induced Hif1-α expression and inhibited DNA damage repair at 2 h after ionizing radiation, which were similar to the effects of calcium chelation (Fig. 6b). Taken together, these results showed that calcium-regulated STAT3 activation acts as the downstream regulator to mediate EMT, Hif1-α signalling and DNA damage repair in HCC cells.

TRPC6 silencing enhances the efficacy of doxorubicin for HCC in vivo

To explore the in vivo role of TRPC6 in the efficacy of doxorubicin for HCC, the stable TRPC6-silenced Huh7 cells were obtained using lentiviral infection with a short hairpin RNA-based vector. The xenograft models were established via subcutaneous injection of cells, and tumour growth was monitored following administration of doxorubicin every other day. Two weeks after implantation, mice were sacrificed and the tumours were dissected and weighted. We found that TRPC6 -silenced cells grew much more slowly than normal cells and were more sensitive to doxorubicin (Fig. 7(a–c)). The calculated coefficient index (CI), as described previously⁴⁶, was less than 1 (CI = 0.682), indicating a synergistic effect of targeting TRPC6 in combination with doxorubicin in vivo.

**Figure 7: TRPC6 silencing enhances the curative efficacy of doxorubicin in Huh7 cells xenografts in nude mice.**

Discussion

HCC is a deadly disease that shows insensitivity to chemotherapy because of easily acquired MDR in many circumstances. Previous studies aiming to overcome MDR or chemo-resistance were restricted to single-target research, which usually resulted in limited curative efficacy. Among the potential key signalling pathways, calcium signalling has been shown to regulate the MDR relevant mechanisms of EMT, Hif1-α signalling and DNA damage repair simultaneously. Moreover, we also verified that the promising calcium channel TRPC6 is responsible for calcium aggregation and MDR induction. Our study showed, for the first time, that calcium channel TRPC6-mediated intracellular calcium aggregation plays a vital role in various mechanisms that regulate MDR in HCC cells.

In this study, we determined that the MDR relevant mechanisms of EMT, Hif1-α signalling and DNA damage repair were all calcium aggregation-dependent in HCC cells. Previous studies revealed that powerful calcium signalling participates in these mechanisms in other circumstances. EGF-induced EMT in breast cancer cells is calcium dependent²⁴. In MCF-7 cells, β-lapachone-induced p-H2A.X foci formation is regulated by calcium⁴⁷. Specifically in our ionizing radiation-induced MDR model, though on the whole calcium chelation could inhibit the DNA damage repair, its effect seemed to be invalid at the later stage (24 h), suggesting the potential of other existed compensatory signaling pathways to regulate DNA damage repair, as the respond to the long-term calcium elimination. On the other hand, in our study, preliminary experiments showed that intracellular calcium chelation failed to attenuate the upregulation of ABC transporters. L-type calcium channel blockers, such as verapamil, were found to antagonize MDR1 expression, which could not be reversed by simple intracellular calcium chelation⁴⁸. Another limitation is that other MDR-relevant mechanisms have not been explored to further determine the interactions of calcium with MDR. Thus, intracellular calcium signalling is very complicated and it was not possible to determine whether it mediates all MDR-relevant mechanisms.

The TRP family of calcium channels are mainly involved in the store-operated Ca²⁺ entry (SOCE)⁴⁹ and non-capacitative Ca²⁺ entry (NCCE)^50,51. Under different stimuli, both TRP channels-induced SOCE and NCCE result in a transient intracellular calcium aggregation and initiated a rapid alteration to the calcium signalling pathway. However, the rapid intracellular calcium accumulation induced by 1-oleoy-2-acetyl-glycerol (OAG), which is thought to be involved in NCCE⁵², was not affected by overexpression of TRPC6³². Therefore, the comprehensive role of TRP channels still remains obscure. Recent reports indicated that TRPC6 also regulates the sustained elevation of basal calcium to influence tumour malignant behaviours. Under hypoxia, TRPC6 causes a sustained elevation of intracellular calcium that is coupled with the development of malignant glioblastoma multiforme cells²⁹. In hepatic stellate cells under hypoxia, the expression of TRPC6 causes a sustained elevation of intracellular calcium, which activates the synthesis of extracellular matrix proteins⁵³. In our study, the sustained elevation of intracellular free calcium was also regulated by TRPC6 overexpression, not only under hypoxia, but also under stimuli of doxorubicin and ionizing radiation. Based on this evidence, we concluded that by modulating sustained intracellular calcium aggregation, the overexpression of TRPC6 has crucially important effect on the adaptive behaviours of tumours.

In vitro, blocking TRPC6 by either siRNA or SKF-96365 attenuated MDR induced by various stimuli. In vivo, targeting TRPC6 showed a synergistic antitumor effect when combined with doxorubicin. Meanwhile, a significant inhibitory role of TRPC6 on HCC cells proliferation was also observed, which was consistent with previous reports^29,32. Thus, the functions of TRPC6 are extensive and not only limited to MDR amelioration.

The downstream signalling pathways regulated by intracellular free calcium are a complicated issue. It is related to disturbing the balance of various kinases/phosphorylases, the activation of calcium binding proteins, the transcription of genes and even alteration of the calcium current by calcium sensitive channels or pumps²¹. Epigenetic regulation, including DNA methylation, protein phosphorylation and histone modification^15,54, have been reported to aid cancer cells to obtain adaptive MDR. In our study, the common calcium signalling downstream event was further explored, and STAT3 was identified. The pathological activation of STAT3 to induce EMT and Hif1-α in human carcinomas has been widely studied^55,56. The cdk5-STAT3 oncogenic pathway plays an important role in the expression of DNA repair genes⁵⁷. Taken together, we demonstrated that activation of STAT3 acts as a bridge to connect calcium and various MDR-related mechanisms.

In summary, our study identified the pivotal role of calcium in mediating mechanisms of EMT, Hif1-α signalling and DNA damage repair to obtain MDR in HCC cells, which were attributed to the sustained accumulation of intracellular free calcium by TRPC6 overexpression. Considering the significant roles of calcium in physical and pathological processes, and the complexity of calcium signalling, simply altering calcium signalling would not render cancer cells more vulnerable and could even have unpredictable systemic consequences²⁸. Therefore, we propose that targeting TRPC6 in HCC might represent a possible novel antineoplastic strategy, especially when combined with chemotherapy.

Methods

Cell culture and reagents

Human HCC cell lines (Huh7 and HepG2, the Shanghai Institution for Biological Science, Shanghai, China) were cultured in DMEM medium (Gibco, Carlsbad, CA, USA) with 10% fetal bovine serum (FBS) (Gibco) and 1% penicillin/streptomycin (Sigma, St. Louis, MO, USA). Cells were normally cultured in a humidified incubator at a constant temperature of 37 °C and 5% CO₂. Doxorubicin, 5-fluorouracil, cisplatin, BAPTA-AM, SKF-96365, DFO and ionomycin were all purchased from Sigma. Fluo4-AM and PluronicF-127 were purchased from Invitrogen (Carlsbad, CA, USA). NSC74859 was purchased from Merck KgaA (Darmstadt, Germany). The stock solutions were prepared in water, PBS or dimethyl sulphoxide (DMSO), as required and stored at −20 °C. Once diluted, the final concentration of DMSO was less than 0.5% to avoid toxicity to cells. To induce EMT with doxorubicin stimuli, HCC cells were treated with 0.2 μg/mL doxorubicin for 24 h. To induce expression of Hif1-α by hypoxia, cells were cultured in a low oxygen incubator with 1% O₂, 5% CO₂ and 94% N₂ for 6 h. Ionizing radiation (X-ray) was produced by an electron accelerator (Siemens, Germany) in the author’s hospital. To obtain DNA damage repair, cells were transiently treated with 10Gy ionizing radiation at 0.5Gy/min and then after 2 h, the cells were normally cultured and the subsequent drug sensitivity assays were performed. For the chelation of intracellular calcium, cells were loaded with 10 μM BAPTA-AM for 1 h before various stimuli. To specifically inhibit TRPC6 function and STAT3 activation respectively, SKF-96365 (10 μM) and NSC74859 (100 μM) were added into the culture medium for the duration of stimulation.

Relative cell viability assays by CCK8

Relative cell viability of drug sensitivity assays was measured by using the Cell Counting Kit-8 (CCK8) kit (Dojindo, Kumamoto, Japan). 3.5 × 10³ cells per well (100 μL media) were seeded into 96 well microplates. After incubation for 12 h, cells were then treated by various stimuli as described above. Cells were then treated with various drugs (doxorubicin, 5-fluorouracil and cisplatin) for 48 h; 10 μL CCK8 solution was added into each well. After incubation for 3 h, the OD values were measured at 450 nm using an MRX II microplate reader (Dynex, Chantilly, VA, Canada). The relative cell viability was determined as a percentage of the untreated control groups. In addition, the IC₅₀ was calculated by the equation: 100a% = 100/(1 + 10^{log[drug]−logIC50}), with the relative cell viability of 100a% and the drug concentration as [drug].

Intracellular calcium measurement

Laser confocal microscopy (LSCM)

For dynamic monitoring of the rapid [Ca²⁺]_c fluctuation, fluo4-AM was chosen as the intracellular free calcium probe. HCC cells were seeded in 33cm confocal specific dishes and grown to 30–70% confluence. The cells were loaded with 5 μM Fluo4-AM in HBSS (Gibco) containing 0.05% PluronicF-127 at 37 °C for 40 min and then washed three times by HBSS to remove the extra Fluo4-AM. To record the [Ca²⁺]_c fluorescence, LSCM was performed using an Olympus laser confocal system (Olympus, IX81-FV1000) with continuous image recording, at a magnification of 40× at 2.343 s intervals, for 30 min. The parameters of LSCM were set as an excitation wavelength of 488 nm and an emission wavelength of 516 nm. Administration of doxorubicin, DFO or ionomycin was performed 3 min after recording began. The relative [Ca²⁺]_c content was presented as the calcium fluorescence intensity.

Fluorescence activated cell sorting (FACS)

To measure the intracellular calcium intensity in HCC cells treated with doxorubicin, hypoxia, ionizing radiation, Fluo4-AM loading was performed as above. The calcium fluorescence intensity was then measured in the fluorescence channel FITC in FACS analysis. The FACS assay was performed using a flow cytometer (FACS Canto II, BD, USA).

Optical microscope observation

HCC cells were seeded in 6-well plates until confluence and then treated with doxorubicin (0.2 μg/mL) for 48 h with or without calcium chelation (10 μM BAPTA-AM for 1 h). Images were recorded under a Zeiss Axio Observer optical microscope using a 40× objective.

Comet assay/Single-cell gel electrophoresis and analysis

The degree of DNA damage was measured and analysed using single-cell gel electrophoresis (Comet assay) and a Comet assay kit (GMS, USA). The experiment was performed according to the manufacturer’s instructions. After receiving ionizing radiation (10Gy) with or without calcium chelation (10 μM BAPTA-AM for 1h), cells were harvested in a density of 1 × 10⁶ cells/mL in HBSS and mixed with liquefied agarose at a 1:9 (v/v) ratio. 100 μL of the mixture was immediately transferred to agarose-coated slides and lysed at 4 °C in the dark for 2 h. The slides were then transferred into the alkaline solution containing 0.6 mM Na-EDTA and 0.18 mM NaOH (pH = 13) at room temperature for 30 min to loosen double-stranded DNA. Later, the slides were removed from the above alkaline solution and electrophoresed at 25 volts in the electrophoresis apparatus at 4 °C for 30 min. After washing with deionized water twice and treatment with ethanol (70%), the slides were dried and stained with the provided dye (50 μL). Images were captured under a fluorescence microscope using the Nikon E2000 Microscope system and the accompanying software (Nikon Corporation, Tokyo, Japan). The comet length of each cell was measured and calculated using the Comet A v.1.0 image analysis software (Cells Biolab, Inc., Beijing, China).

RNA interference (siRNA)

Huh7 and HepG2 cells were transfected by TRPC6 siRNA, Twist siRNA, Hif1-α siRNA, H2A.X siRNA or negative control (NC) siRNA (Santa Cruz, CA, USA) at 25 nmol/L using Lipofectamine 3000 (Invitrogen), according to the manufacturer’s instructions. After siRNA transfection for 6 h, cells were cultured in complete medium for the designated time. The transfection efficiency was assessed by quantitative real-time reverse transcription PCR (qRT-PCR) and western blotting at 24 h and 48 h after transfection. All experiments were performed 24 h after siRNA transfection.

Western blotting

HCC cells were seeded in 6-well plates at a density of 1.5 × 10⁵ cells per well and incubated for 12 h. After various treatments, the cells were washed with PBS twice and harvested immediately in ice-cold lysis buffer (150 μL) (Cell Signaling, Danvers, MA, USA). After the protein lysates were quantified using a Bicinchoninic Acid Protein Assay kit (Beyotime Institute of Biotechnology, Shanghai, China), protein solutions (40 μg/L) were separated using 10% SDS–PAGE and transferred electrophoretically to PVDF membranes (Millipore, Billerica, MA, USA). Membranes were blocked using 5% bovine serum albumin (BSA) in Tris-buffered saline (TBS) with 0.1% Tween-20 (TBST) for 1 h at room temperature and then incubated at 4 °C with anti-E-Cadherin, anti-Vimentin, anti-Claudin1, anti-phospho-ATM, anti-ATM, anti-phospho-ATR, anti-ATR, anti-phospho-H2A.X, anti-H2A.X, anti-phospho-Erk1/2 (Thr202/Tyr204), anti-Erk1/2, anti-phospho-AKT (Ser473), anti-AKT, anti-phospho-STAT3 (Tyr705), anti-STAT3 (Cell Signaling), anti-Hif1-α, anti-TRPC6 and anti-Twist (Abcam, Shanghai, China) antibodies, separately, at a dilution of 1:1000–2000, according to the manufacturer’s instructions. Protein loading was normalized using an anti-GAPDH antibody (1:5000, Kangchen Biotechnology, China). After incubating with the primary antibodies for 8h, membranes were then washed three times (10 min each) with TBST and incubated with the appropriate anti-mouse and anti-rabbit HRP-conjugated secondary antibodies (1:2000; GE Healthcare, Piscataway, NJ, USA). Images were developed using the ECL reagent (Millipore), and acquired using a VersaDoc Digital Imaging System (Bio-Rad).

qRT-PCR

The total RNA of each sample was extracted and purified using the TRIzol reagent (Invitrogen), according to the manufacturer’s instructions. A PrimeScript RT reagent kit (Takara Biotechnology Co., Dalian, China) was used for reverse transcription of RNA (1 μg) to cDNA, which was amplified according to the following program: 95 °C for 30 s; then 40 cycles of 95 °C for 5 s and 60 °C for 34 s; 95 °C for 15 s; 60 °C for 1 min and 95 °C for 15 s. The procedure was realized in a StepOne Plus Real Time PCR instrument (Applied Biosystems, Carlsbad, CA, USA) using equal volumes of cDNA (2 μL) with the SYBR Premix Ex Taq II kit (Takara), according to the manufacturer’s instructions. Relative quantitation analysis was performed with reference to β-actin RNA using the comparative cycle threshold (CT) method. The primer sequences were listed as followed: TRPC6, Forward (5′-3′): GACATCTTCAAGTTCATGGTCACA, Reverse (5′-3′): ATCAGCGTCATCCTCAATTTC; β-actin, Forward (5′-3′): CGTGCGTGACATTAAAGAG, Reverse (5′-3′): TTGCCGATAGTGATGACCT.

Construction and production of lentiviral vectors for stable TRPC6 silencing

The GV115 lentiviral particles containing short hairpin sequence targeting the human TRPC6 gene (GenBank ID: NM_004621) as well as the negative sequence, were purchased from GeneChem (Shanghai, China). The sequences for the siRNA targeting TRPC6 gene and the non-silencing siRNA were as follows: TRPC6, TGGGTAATAGGCATGATAT; non-silencing siRNA, TTCTCCGAACGTGTCACGT. The oligonucleotides designed according to the structure of the siRNA were TRPC6 sense 5′-CCGGCCTGGGTAATAGGCATGATATCTCGAGATATCATGCCTATTACCCAGGTTTTTG-3′ and antisense 5′-AATTCAAAAACCTGGGTAATAGGCATGATATCTCGAGATATCATGCCTATTACCCAGG-3′, negative control sense 5′-CCGGTTCTCCGAACGTGTCACGTTTCAAGAGAACGTGACACGTTCGGAGAATTTTTG-3′ and antisense 5′-AATTCAAAAATTCTCCGAACGTGTCACGTTCTCTTGAAACGTGACACGTTCGGAGAA-3′. The oligonucleotides containing TRPC6 siRNA or control siRNA sequences were constructed into plasmids, which were then cloned into the lentiviral vectors encoding a green fluorescent protein (GFP) sequence designated as LV-shTRPC6 and LV-NC. To generate the lentivirus, the recombinant vector and packaged plasmids were co-transduced into 293 T cells using lipofectamine 2000 (Invitrogen, USA). The final titre of the recombinant virus was 5 × 10⁸ TU/mL.

HCC cells in vivo xenograft

This assay studied the effect of TRPC6 silencing on curative efficacy of doxorubicin to HCC in vivo. Huh7 cells were infected with lentivirus at MOI of 10 (LV-NC, LV shTRPC6), and 72 hours after infection, the infection efficiency was high enough with more than 90% of the cells expressing GFP. The cells (suspended in PBS, 1 × 10⁶ cells/100 μL) were injected subcutaneously into the right axillary fossa of twenty-four BALB/c athymic nude mice (Experiment Animal Centre, Shanghai, China), weighing 20–25g that were 3–4 weeks old (two groups for LV-NC, two groups for LV shTRPC6, n = 6 per group). Tumour length (L) and width (W) were measured every other day, and tumour volumes were calculated as follows: (L × W²)/2⁵⁸. After the tumour volumes reached 100–150 mm³, half of the mice were intraperitoneally injected with doxorubicin (4 mg/kg in normal saline) and the other mice with the equal volume of normal saline. Doxorubicin was delivered intraperitoneally every two days for 2 weeks. After 2 weeks, mice were sacrificed by cervical dislocation, then tumours were resected and tumour weights were measured. The animal experiments were carried out in “accordance” with the approved guidelines of the Ethics Committee on Animal Experimentation of Zhejiang University, Hangzhou, China.

Statistical analyses

Statistical analyses were performed using Prism 5 (GraphPad, San Diego, CA, USA). Statistical tests are detailed in the figure legends. For all experiments, p < 0.05 was considered statistically significant.

Additional Information

How to cite this article: Wen, L. et al. Regulation of Multi-drug Resistance in hepatocellular carcinoma cells is TRPC6/Calcium Dependent. Sci. Rep. 6, 23269; doi: 10.1038/srep23269 (2016).

References

Lage, H. An overview of cancer multidrug resistance: a still unsolved problem. Cell Mol Life Sci 65, 3145–3167, doi: 10.1007/s00018-008-8111-5 (2008).
Article CAS PubMed Google Scholar
Szakacs, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C. & Gottesman, M. M. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5, 219–234, doi: 10.1038/nrd1984 (2006).
Article CAS PubMed Google Scholar
Milane, L., Ganesh, S., Shah, S., Duan, Z. F. & Amiji, M. Multi-modal strategies for overcoming tumor drug resistance: hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology. J Control Release 155, 237–247, doi: 10.1016/j.jconrel.2011.03.032 (2011).
Article CAS PubMed PubMed Central Google Scholar
Wilson, W. R. & Hay, M. P. Targeting hypoxia in cancer therapy. Nat Rev Cancer 11, 393–410, doi: 10.1038/nrc3064 (2011).
Article CAS PubMed Google Scholar
Gottesman, M. M. & Pastan, I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62, 385–427, doi: 10.1146/annurev.bi.62.070193.002125 (1993).
Article CAS PubMed Google Scholar
Li, Q. Q. et al. Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin Cancer Res 15, 2657–2665, doi: 10.1158/1078-0432.CCR-08-2372 (2009).
Article CAS PubMed Google Scholar
van Zijl, F. et al. A human model of epithelial to mesenchymal transition to monitor drug efficacy in hepatocellular carcinoma progression. Mol Cancer Ther 10, 850–860, doi: 10.1158/1535-7163.MCT-10-0917 (2011).
Article CAS PubMed Google Scholar
Comerford, K. M. et al. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 62, 3387–3394 (2002).
CAS PubMed Google Scholar
Park, J. G. et al. MDR1 gene expression: its effect on drug resistance to doxorubicin in human hepatocellular carcinoma cell lines. J Natl Cancer Inst 86, 700–705 (1994).
Article CAS Google Scholar
Venkatesha, V. A. et al. Sensitization of pancreatic cancer stem cells to gemcitabine by Chk1 inhibition. Neoplasia 14, 519–525 (2012).
Article CAS Google Scholar
Wang, L., Mosel, A. J., Oakley, G. G. & Peng, A. Deficient DNA damage signaling leads to chemoresistance to cisplatin in oral cancer. Mol Cancer Ther 11, 2401–2409, doi: 10.1158/1535-7163.MCT-12-0448 (2012).
Article CAS PubMed PubMed Central Google Scholar
Yang, Z. J., Chee, C. E., Huang, S. & Sinicrope, F. A. The role of autophagy in cancer: therapeutic implications. Mol Cancer Ther 10, 1533–1541, doi: 10.1158/1535-7163.MCT-11-0047 (2011).
Article CAS PubMed PubMed Central Google Scholar
Martin, V. et al. Melatonin-induced methylation of the ABCG2/BCRP promoter as a novel mechanism to overcome multidrug resistance in brain tumour stem cells. Br J Cancer 108, 2005–2012, doi: 10.1038/bjc.2013.188 (2013).
Article CAS PubMed PubMed Central Google Scholar
Baguley, B. C. Tumor stem cell niches: a new functional framework for the action of anticancer drugs. Recent Pat Anticancer Drug Discov 1, 121–127 (2006).
Article CAS Google Scholar
Wu, Q., Yang, Z., Nie, Y., Shi, Y. & Fan, D. Multi-drug resistance in cancer chemotherapeutics: mechanisms and lab approaches. Cancer Lett 347, 159–166, doi: 10.1016/j.canlet.2014.03.013 (2014).
Article CAS PubMed Google Scholar
Teicher, B. A. Acute and chronic in vivo therapeutic resistance. Biochem Pharmacol 77, 1665–1673, doi: 10.1016/j.bcp.2009.01.006 (2009).
Article CAS PubMed Google Scholar
Petraccia, L. et al. [MDR (multidrug resistance) in hepatocarcinoma clinical-therapeutic implications]. Clin Ter 154, 325–335 (2003).
CAS PubMed Google Scholar
Luo, D., Wang, Z., Wu, J., Jiang, C. & Wu, J. The role of hypoxia inducible factor-1 in hepatocellular carcinoma. Biomed Res Int 2014, 409272, doi: 10.1155/2014/409272 (2014).
Article CAS PubMed PubMed Central Google Scholar
van Zijl, F. et al. Epithelial-mesenchymal transition in hepatocellular carcinoma. Future Oncol 5, 1169–1179, doi: 10.2217/fon.09.91 (2009).
Article CAS PubMed Google Scholar
Zhang, H. et al. Targeting human 8-oxoguanine DNA glycosylase (hOGG1) to mitochondria enhances cisplatin cytotoxicity in hepatoma cells. Carcinogenesis 28, 1629–1637, doi: 10.1093/carcin/bgm072 (2007).
Article CAS PubMed Google Scholar
Berridge, M. J., Bootman, M. D. & Roderick, H. L. Calcium signalling: dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol 4, 517–529, doi: 10.1038/nrm1155 (2003).
Article CAS PubMed Google Scholar
Hu, J. et al. Downregulation of transcription factor Oct4 induces an epithelial-to-mesenchymal transition via enhancement of Ca²⁺ influx in breast cancer cells. Biochem Biophys Res Commun 411, 786–791, doi: 10.1016/j.bbrc.2011.07.025 (2011).
Article CAS PubMed Google Scholar
Davis, F. M. et al. Non-stimulated, agonist-stimulated and store-operated Ca²⁺ influx in MDA-MB-468 breast cancer cells and the effect of EGF-induced EMT on calcium entry. PLoS One 7, e36923, doi: 10.1371/journal.pone.0036923 (2012).
Article CAS ADS PubMed PubMed Central Google Scholar
Davis, F. M. et al. Induction of epithelial-mesenchymal transition (EMT) in breast cancer cells is calcium signal dependent. Oncogene 33, 2307–2316, doi: 10.1038/onc.2013.187 (2014).
Article CAS PubMed Google Scholar
Mottet, D. et al. ERK and calcium in activation of HIF-1. Ann N Y Acad Sci 973, 448–453 (2002).
Article CAS ADS Google Scholar
Mottet, D. et al. Role of ERK and calcium in the hypoxia-induced activation of HIF-1. J Cell Physiol 194, 30–44, doi: 10.1002/jcp.10176 (2003).
Article CAS PubMed Google Scholar
Bentle, M. S., Reinicke, K. E., Bey, E. A., Spitz, D. R. & Boothman, D. A. Calcium-dependent modulation of poly(ADP-ribose) polymerase-1 alters cellular metabolism and DNA repair. J Biol Chem 281, 33684–33696, doi: 10.1074/jbc.M603678200 (2006).
Article CAS PubMed Google Scholar
Monteith, G. R., McAndrew, D., Faddy, H. M. & Roberts-Thomson, S. J. Calcium and cancer: targeting Ca²⁺ transport. Nat Rev Cancer 7, 519–530, doi: 10.1038/nrc2171 (2007).
Article CAS PubMed Google Scholar
Chigurupati, S. et al. Receptor channel TRPC6 is a key mediator of Notch-driven glioblastoma growth and invasiveness. Cancer Res 70, 418–427, doi: 10.1158/0008-5472.CAN-09-2654 (2010).
Article CAS PubMed Google Scholar
Ma, X. et al. Transient receptor potential channel TRPC5 is essential for P-glycoprotein induction in drug-resistant cancer cells. Proc Natl Acad Sci USA 109, 16282–16287, doi: 10.1073/pnas.1202989109 (2012).
Article ADS PubMed Google Scholar
Yu, Y. et al. PDGF stimulates pulmonary vascular smooth muscle cell proliferation by upregulating TRPC6 expression. Am J Physiol Cell Physiol 284, C316–330, doi: 10.1152/ajpcell.00125.2002 (2003).
Article CAS PubMed Google Scholar
El Boustany, C. et al. Capacitative calcium entry and transient receptor potential canonical 6 expression control human hepatoma cell proliferation. Hepatology 47, 2068–2077, doi: 10.1002/hep.22263 (2008).
Article CAS PubMed Google Scholar
Salnikow, K. et al. Depletion of intracellular ascorbate by the carcinogenic metals nickel and cobalt results in the induction of hypoxic stress. J Biol Chem 279, 40337–40344, doi: 10.1074/jbc.M403057200 (2004).
Article CAS PubMed Google Scholar
Dongiovanni, P. et al. Iron depletion by deferoxamine up-regulates glucose uptake and insulin signaling in hepatoma cells and in rat liver. Am J Pathol 172, 738–747, doi: 10.2353/ajpath.2008.070097 (2008).
Article CAS PubMed PubMed Central Google Scholar
Berridge, M. J., Lipp, P. & Bootman, M. D. The versatility and universality of calcium signalling. Nat Rev Mol Cell Biol 1, 11–21, doi: 10.1038/35036035 (2000).
Article CAS PubMed Google Scholar
Chen, B. W. et al. Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells. Mol Cancer Ther 14, 1805–1815, doi: 10.1158/1535-7163.MCT-15-0029 (2015).
Article CAS PubMed PubMed Central Google Scholar
Hu, Q. D. et al. NSC 74859 enhances doxorubicin cytotoxicity via inhibition of epithelial-mesenchymal transition in hepatocellular carcinoma cells. Cancer Lett 325, 207–213, doi: 10.1016/j.canlet.2012.07.003 (2012).
Article CAS PubMed Google Scholar
Celeste, A. et al. Histone H2AX phosphorylation is dispensable for the initial recognition of DNA breaks. Nat Cell Biol 5, 675–679, doi: 10.1038/ncb1004 (2003).
Article CAS PubMed Google Scholar
Xu, S. H. et al. ACK1 promotes gastric cancer epithelial-mesenchymal transition and metastasis through AKT-POU2F1-ECD signalling. J Pathol, doi: 10.1002/path.4515 (2015).
Li, W. & Melton, D. W. Cisplatin regulates the MAPK kinase pathway to induce increased expression of DNA repair gene ERCC1 and increase melanoma chemoresistance. Oncogene 31, 2412–2422, doi: 10.1038/onc.2011.426 (2012).
Article CAS PubMed Google Scholar
Zhao, D. et al. Cytoplasmic p27 promotes epithelial-mesenchymal transition and tumor metastasis via STAT3-mediated Twist1 upregulation. Oncogene, doi: 10.1038/onc.2014.473 (2015).
Pawlus, M. R., Wang, L. & Hu, C. J. STAT3 and HIF1alpha cooperatively activate HIF1 target genes in MDA-MB-231 and RCC4 cells. Oncogene 33, 1670–1679, doi: 10.1038/onc.2013.115 (2014).
Article CAS PubMed Google Scholar
Liu, W. L. et al. Targeting Phosphatidylinositide3-Kinase/Akt pathway by BKM120 for radiosensitization in hepatocellular carcinoma. Oncotarget 5, 3662–3672 (2014).
PubMed PubMed Central Google Scholar
Siddiquee, K. et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci USA 104, 7391–7396, doi: 10.1073/pnas.0609757104 (2007).
Article CAS ADS PubMed Google Scholar
Lin, L. et al. The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling. Oncogene 28, 961–972, doi: 10.1038/onc.2008.448 (2009).
Article CAS PubMed PubMed Central Google Scholar
Wang, J. et al. Overexpression of von Hippel-Lindau protein synergizes with doxorubicin to suppress hepatocellular carcinoma in mice. J Hepatol 55, 359–368, doi: 10.1016/j.jhep.2010.10.043 (2011).
Article CAS PubMed Google Scholar
Tagliarino, C. et al. Mu-calpain activation in beta-lapachone-mediated apoptosis. Cancer Biol Ther 2, 141–152 (2003).
Article CAS Google Scholar
Sulova, Z. et al. Does any relationship exist between P-glycoprotein-mediated multidrug resistance and intracellular calcium homeostasis. Gen Physiol Biophys 28 Spec No Focus, F89–95 (2009).
PubMed Google Scholar
Yu, Y. et al. Enhanced expression of transient receptor potential channels in idiopathic pulmonary arterial hypertension. Proc Natl Acad Sci USA 101, 13861–13866, doi: 10.1073/pnas.0405908101 (2004).
Article CAS ADS PubMed Google Scholar
Ambudkar, I. S. Ca²⁺ signaling microdomains:platforms for the assembly and regulation of TRPC channels. Trends Pharmacol Sci 27, 25–32, doi: 10.1016/j.tips.2005.11.008 (2006).
Article CAS PubMed Google Scholar
Minke, B. TRP channels and Ca²⁺ signaling. Cell Calcium 40, 261–275, doi: 10.1016/j.ceca.2006.05.002 (2006).
Article CAS PubMed PubMed Central Google Scholar
Bird, G. S. et al. Mechanisms of phospholipase C-regulated calcium entry. Curr Mol Med 4, 291–301 (2004).
Article CAS Google Scholar
Iyer, S. C., Kannan, A., Gopal, A., Devaraj, N. & Halagowder, D. Receptor channel TRPC6 orchestrate the activation of human hepatic stellate cell under hypoxia condition. Exp Cell Res 336, 66–75, doi: 10.1016/j.yexcr.2015.03.023 (2015).
Article CAS PubMed Google Scholar
Mahajan, K. & Mahajan, N. P. ACK1/TNK2 tyrosine kinase: molecular signaling and evolving role in cancers. Oncogene, doi: 10.1038/onc.2014.350 (2014).
Niu, G. et al. Signal transducer and activator of transcription 3 is required for hypoxia-inducible factor-1alpha RNA expression in both tumor cells and tumor-associated myeloid cells. Mol Cancer Res 6, 1099–1105, doi: 10.1158/1541-7786.MCR-07-2177 (2008).
Article CAS PubMed PubMed Central Google Scholar
Wendt, M. K., Balanis, N., Carlin, C. R. & Schiemann, W. P. STAT3 and epithelial-mesenchymal transitions in carcinomas. JAKSTAT 3, e28975, doi: 10.4161/jkst.28975 (2014).
Article PubMed PubMed Central Google Scholar
Courapied, S. et al. The cdk5 kinase regulates the STAT3 transcription factor to prevent DNA damage upon topoisomerase I inhibition. J Biol Chem 285, 26765–26778, doi: 10.1074/jbc.M109.092304 (2010).
Article CAS PubMed PubMed Central Google Scholar
Naito, S., von Eschenbach, A. C., Giavazzi, R. & Fidler, I. J. Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice. Cancer Res 46, 4109–4115 (1986).
CAS PubMed Google Scholar

Download references

Acknowledgements

This study was financially supported by the National Key Basic Research Program of China (2014CB542101, TB Liang), the National Natural Science Foundation of China (81472212, to TB Liang; 81302071, to W Chen; 81171884, to XL Bai; and 31090360, to XH Feng), the National High Technology Research and Development Program 863 of China (SS2014AA020534, W Chen), Project 111 (XH Feng), and Project 985 (to XH Feng).

Author information

Liang Wen and Chao Liang: These authors contributed equally to this work.

Authors and Affiliations

Department of General Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, PR China
Liang Wen, Enjiang Chen, Wei Chen, Xiao Zhi, Tao Wei, Guogang Li, Weihua Gong, Xueli Bai & Tingbo Liang
Department of General Surgery, Ningbo Medical Treatment Center Lihuili Hospital, Ningbo, PR China
Chao Liang
Department of Neurosurgery Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, PR China
Feng Liang
Department of Hepatobiliary and Pancreatic Surgery, Henan Province People’s Hospital, Henan, PR China
Fei Xue
Center for Immunology and Microbial Disease,Albany Medical College, ME-205 47 New Scotland Ave., Albany, MC-151, New York, USA
Qi Yang
Life Sciences Institute and Innovation Center for Cell Signaling Network, Zhejiang University, Hangzhou, PR China
Xinhua Feng
Collaborative Innovation Center for Cancer Medicine, Zhejiang University, Hangzhou, PR China
Tingbo Liang

Authors

Liang Wen
View author publications
You can also search for this author in PubMed Google Scholar
Chao Liang
View author publications
You can also search for this author in PubMed Google Scholar
Enjiang Chen
View author publications
You can also search for this author in PubMed Google Scholar
Wei Chen
View author publications
You can also search for this author in PubMed Google Scholar
Feng Liang
View author publications
You can also search for this author in PubMed Google Scholar
Xiao Zhi
View author publications
You can also search for this author in PubMed Google Scholar
Tao Wei
View author publications
You can also search for this author in PubMed Google Scholar
Fei Xue
View author publications
You can also search for this author in PubMed Google Scholar
Guogang Li
View author publications
You can also search for this author in PubMed Google Scholar
Qi Yang
View author publications
You can also search for this author in PubMed Google Scholar
Weihua Gong
View author publications
You can also search for this author in PubMed Google Scholar
Xinhua Feng
View author publications
You can also search for this author in PubMed Google Scholar
Xueli Bai
View author publications
You can also search for this author in PubMed Google Scholar
Tingbo Liang
View author publications
You can also search for this author in PubMed Google Scholar

Contributions

L.W., C.L., E.C. and X.Z. performed research; L.W., C.L., W.C., T.L. and X.B. designed research; F.L., G.L., Q.Y., W.G. and X.F. helped to promote the design. L.W., C.L. and T.W. analyzed the data; L.W. wrote the paper. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Tingbo Liang.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Video 1 (MOV 3416 kb)

Supplementary Video 2 (MOV 3693 kb)

Supplementary Video 3 (MOV 4077 kb)

Supplementary Video 4 (MOV 3286 kb)

Supplementary Video 5 (MOV 2800 kb)

Supplementary Video 6 (MOV 1837 kb)

Supplementary Video 7 (MOV 2929 kb)

Supplementary Video 8 (MOV 3110 kb)

Supplementary Information (DOC 4194 kb)

Rights and permissions

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Reprints and permissions

About this article

Cite this article

Wen, L., Liang, C., Chen, E. et al. Regulation of Multi-drug Resistance in hepatocellular carcinoma cells is TRPC6/Calcium Dependent. Sci Rep 6, 23269 (2016). https://doi.org/10.1038/srep23269

Download citation

Received: 24 August 2015
Accepted: 03 March 2016
Published: 24 March 2016
DOI: https://doi.org/10.1038/srep23269

This article is cited by

Targeting liver cancer stem cell through EpCAM therapy targeted with chemotherapy endorse enhanced progression in hepatocellular carcinoma
- Vasanthakumar Sekar
- Ramakrishnan Veerabathiran
- Ganesan Sivamani
Egyptian Liver Journal (2023)
Transient Receptor Potential Canonical 6 (TRPC6) Channel in the Pathogenesis of Diseases: A Jack of Many Trades
- Uzma Saqib
- Sreepadaarchana Munjuluri
- Krishnan Hajela
Inflammation (2023)
Blocked metabotropic glutamate receptor 5 enhances chemosensitivity in hepatocellular carcinoma and attenuates chemotoxicity in the normal liver by regulating DNA damage
- Hui-Min Yang
- Tian-Zhong Hou
- Hong Zhang
Cancer Gene Therapy (2022)
Canonical transient receptor potential channels and their modulators: biology, pharmacology and therapeutic potentials
- Yuan-Yuan Gao
- Wen Tian
- Xiao-Qiang Li
Archives of Pharmacal Research (2021)
LncRNA CRNDE facilitates epigenetic suppression of CELF2 and LATS2 to promote proliferation, migration and chemoresistance in hepatocellular carcinoma
- Shu-Cai Xie
- Jian-Quan Zhang
- Yi-Jun Yang
Cell Death & Disease (2020)

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.